Advertisement

Topics

Carfilzomib Combos Deemed Safe in Multiple Myeloma

17:32 EDT 14 Sep 2018 | OncLive

Updated safety data of the ASPIRE and ENDEAVOR trials showed that carfilzomib-based (Kyprolis) regimens demonstrate benefit across patient populations of multiple myeloma.

Original Article: Carfilzomib Combos Deemed Safe in Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "Carfilzomib Combos Deemed Safe in Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement